Basic Information
RNALocate ID: | RLID:11001659 |
RNA Symbol: | hsa-miR-15b-5p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-15b-5p |
RNA ID: | miRBase:MIMAT0000417 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 22211110 |
Tissue/Cell Line: | Breast milk |
Method: | Next-generation RNA sequencing |
The expression profile of selected miRNAs in breast milk exosomes. Originally published in Int J Biol Sci. Zhou Q, et al, 2012. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | Distribution and characterization of miRNAs in breast milk exosomes. (A) Distribution of pre-miRNAs. Out of 1,424 pre-miRNAs deposited in miRBase 17.0 (blue circle), 87 (6.11%) pre-miRNAs have been designated as immune-related pre-miRNAs based on annotation in the Pathway Central database (SABiosciences, MD, USA). Immune-related pre-miRNAs (59 of 452, 13.05%) are enriched in breast milk exosomes (red circle). χ2 test: Number of immune-related miRNAs and others detected in breast milk exosomes compared with the total entries in miRBase 17.0. (B) Top ten most highly expressed unique miRNAs. Plot of the unique miRNAs (starting from the miRNA with the highest counts, x-axis) versus their cumulative % of the total counts from 602 unique miRNAs detected in breast milk exosomes for each small RNA library. Values are means ± s.d. The dashed horizontal line at 62.3% represents the level of the top ten unique miRNAs and the % of individual miRNAs is marked by the gray line. (C-E) The expression profile of selected miRNAs in breast milk exosomes. (C) 59 immune-related pre-miRNAs; (D) miR-17-92 cluster and paralogous clusters, and (E) ten well-characterized tissue-specific pre-miRNAs. Data are collected from Figure 2. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001717 | Cytoplasm | Neural progenitor cells | 21363885 |
RLID:01001718 | Cytoplasm | Cell line (HeLa) | 21695135 |
RLID:01001719 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001720 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001721 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001722 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001723 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001724 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11001654 | Exosome | Glioblastoma cells | 19011622 |
RLID:11001655 | Exosome | Lung adenocarcinoma epithelial cell line (A549) | 20615901 |
RLID:11001656 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
RLID:11001657 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11001658 | Exosome | Renal cancer cells | 21670082 |
RLID:11001660 | Exosome | Brain tissue | 23382797 |
RLID:11001661 | Exosome | Plasma | 23663360 |
RLID:11001662 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11001663 | Exosome | Breast cancer cell lines (MCF-7|MDA-MB-231) | 24468161 |
RLID:11001664 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11001665 | Microvesicle | Glioblastoma cells | 19011622 |
RLID:11001666 | Microvesicle | Lung epithelial carcinoma cell line (A549) | 20615901 |
RLID:11001667 | Microvesicle | Plasma | 23077538 |
RLID:11001668 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000070 | Exosome | Endothelial cells|Epithelial cells | |
RLID-D:11000345 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-15b-5p | Splenic marginal zone lymphoma | MNDR-E-MI-18279 |
MNDR | hsa-miR-15b-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-18280 |
MNDR | hsa-miR-15b-5p | Tongue squamous cell carcinoma | MNDR-E-MI-18281 |
MNDR | hsa-miR-15b-5p | Oral squamous cell carcinoma | MNDR-E-MI-18282 |
MNDR | hsa-miR-15b-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-18283 |
MNDR | hsa-miR-15b-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-18284 |
MNDR | hsa-miR-15b-5p | Lymphoma | MNDR-E-MI-18285 |
MNDR | hsa-miR-15b-5p | Lymphoma non-hodgkin | MNDR-E-MI-18286 |
MNDR | hsa-miR-15b-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-18287 |
MNDR | hsa-miR-15b-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-18288 |
MNDR | hsa-miR-15b-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-18289 |
MNDR | hsa-miR-15b-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-18290 |
MNDR | hsa-miR-15b-5p | Her2-receptor positive breast cancer | MNDR-E-MI-18291 |
MNDR | hsa-miR-15b-5p | Acute promyelocytic leukemia | MNDR-E-MI-18292 |
MNDR | hsa-miR-15b-5p | Breast cancer luminal | MNDR-E-MI-18293 |
MNDR | hsa-miR-15b-5p | Niemann-pick disease type c | MNDR-E-MI-18294 |
MNDR | hsa-miR-15b-5p | Lupus nephritis | MNDR-E-MI-18295 |
MNDR | hsa-miR-15b-5p | Prostate cancer | MNDR-E-MI-18296 |
MNDR | hsa-miR-15b-5p | Gastric cancer | MNDR-E-MI-18297 |
MNDR | hsa-miR-15b-5p | Gastric lymphoma | MNDR-E-MI-18298 |
MNDR | hsa-miR-15b-5p | Alzheimer disease | MNDR-E-MI-18299 |
MNDR | hsa-miR-15b-5p | Encephalitis japanese | MNDR-E-MI-18300 |
MNDR | hsa-miR-15b-5p | Intracranial aneurysm | MNDR-E-MI-18301 |
MNDR | hsa-miR-15b-5p | Esophageal carcinoma | MNDR-E-MI-18302 |
MNDR | hsa-miR-15b-5p | Dysautonomia familial | MNDR-E-MI-18303 |
MNDR | hsa-miR-15b-5p | Seizures | MNDR-E-MI-18304 |
MNDR | hsa-miR-15b-5p | Leukemia | MNDR-E-MI-18305 |
MNDR | hsa-miR-15b-5p | Huntington disease | MNDR-E-MI-18306 |
MNDR | hsa-miR-15b-5p | Chorea | MNDR-E-MI-18307 |
MNDR | hsa-miR-15b-5p | Cardiovascular disease | MNDR-E-MI-18308 |
MNDR | hsa-miR-15b-5p | Carotid stenosis | MNDR-E-MI-18309 |
MNDR | hsa-miR-15b-5p | Moyamoya disease | MNDR-E-MI-18310 |
MNDR | hsa-miR-15b-5p | Lung cancer | MNDR-E-MI-18311 |
MNDR | hsa-miR-15b-5p | Fragile x syndrome | MNDR-E-MI-18312 |
MNDR | hsa-miR-15b-5p | Parkinson disease | MNDR-E-MI-18313 |
MNDR | hsa-miR-15b-5p | Niemann-pick disease | MNDR-E-MI-18314 |
MNDR | hsa-miR-15b-5p | Basal-like breast cancer | MNDR-E-MI-18315 |
MNDR | hsa-miR-15b-5p | Thyroid cancer | MNDR-E-MI-18316 |
MNDR | hsa-miR-15b-5p | Pituitary neoplasms | MNDR-E-MI-18317 |
MNDR | hsa-miR-15b-5p | Pancreatic cancer | MNDR-E-MI-18318 |
MNDR | hsa-miR-15b-5p | Malignant melanoma | MNDR-E-MI-18319 |
MNDR | hsa-miR-15b-5p | Gaucher disease | MNDR-E-MI-18320 |
MNDR | hsa-miR-15b-5p | Rectum adenocarcinoma | MNDR-E-MI-18321 |
MNDR | hsa-miR-15b-5p | Nephroblastoma | MNDR-E-MI-18322 |
MNDR | hsa-miR-15b-5p | Colon cancer | MNDR-E-MI-18323 |
MNDR | hsa-miR-15b-5p | Colon adenocarcinoma | MNDR-E-MI-18324 |
MNDR | hsa-miR-15b-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-18325 |
MNDR | hsa-miR-15b-5p | Familial ovarian cancer | MNDR-E-MI-18326 |
MNDR | hsa-miR-15b-5p | Acromegaly | MNDR-E-MI-18327 |
MNDR | hsa-miR-15b-5p | Prostate adenocarcinoma | MNDR-E-MI-18328 |
MNDR | hsa-miR-15b-5p | Carcinoma ductal breast | MNDR-E-MI-18329 |
MNDR | hsa-miR-15b-5p | Glioblastoma | MNDR-E-MI-18330 |
MNDR | hsa-miR-15b-5p | Astrocytoma | MNDR-E-MI-18331 |
MNDR | hsa-miR-15b-5p | Glioma | MNDR-E-MI-18332 |
MNDR | hsa-miR-15b-5p | Oligodendroglioma | MNDR-E-MI-18333 |
MNDR | hsa-miR-15b-5p | Neurilemmoma | MNDR-E-MI-18334 |
MNDR | hsa-miR-15b-5p | Chordoma | MNDR-E-MI-18335 |
MNDR | hsa-miR-15b-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-18336 |
MNDR | hsa-miR-15b-5p | Osteosarcoma | MNDR-E-MI-18337 |
MNDR | hsa-miR-15b-5p | Liposarcoma | MNDR-E-MI-18338 |
MNDR | hsa-miR-15b-5p | Liver cancer | MNDR-E-MI-18339 |
MNDR | hsa-miR-15b-5p | Cervical adenocarcinoma | MNDR-E-MI-18340 |
MNDR | hsa-miR-15b-5p | Gastric adenocarcinoma | MNDR-E-MI-18341 |
MNDR | hsa-miR-15b-5p | Cervical squamous cell carcinoma | MNDR-E-MI-18342 |
MNDR | hsa-miR-15b-5p | Pituitary adenoma | MNDR-E-MI-18343 |
MNDR | hsa-miR-15b-5p | Lung squamous cell carcinoma | MNDR-E-MI-18344 |
MNDR | hsa-miR-15b-5p | Carcinoma lung non-small-cell | MNDR-E-MI-18345 |
MNDR | hsa-miR-15b-5p | Lung adenocarcinoma | MNDR-E-MI-18346 |
MNDR | hsa-miR-15b-5p | Adrenocortical cancer | MNDR-E-MI-18347 |
MNDR | hsa-miR-15b-5p | Ovarian carcinoma | MNDR-E-MI-18348 |
MNDR | hsa-miR-15b-5p | Bladder urothelial carcinoma | MNDR-E-MI-18349 |
MNDR | hsa-miR-15b-5p | Pancreatic adenocarcinoma | MNDR-E-MI-18350 |
MNDR | hsa-miR-15b-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-18351 |
MNDR | hsa-miR-15b-5p | Carcinoma renal cell | MNDR-E-MI-18352 |
MNDR | hsa-miR-15b-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-18353 |
MNDR | hsa-miR-15b-5p | Clear cell renal cell carcinoma | MNDR-E-MI-18354 |
MNDR | hsa-miR-15b-5p | Cholangiocarcinoma | MNDR-E-MI-18355 |
MNDR | hsa-miR-15b-5p | Esophageal cancer | MNDR-E-MI-18356 |
MNDR | hsa-miR-15b-5p | Oncocytoma | MNDR-E-MI-18357 |
MNDR | hsa-miR-15b-5p | Lung small cell carcinoma | MNDR-E-MI-18358 |
MNDR | hsa-miR-15b-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-18359 |
MNDR | hsa-miR-15b-5p | Heart failure | MNDR-E-MI-18360 |
MNDR | hsa-miR-15b-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-18361 |
MNDR | hsa-miR-15b-5p | Breast invasive carcinoma | MNDR-E-MI-18362 |
MNDR | hsa-miR-15b-5p | Hepatocellular carcinoma | MNDR-E-MI-18363 |
MNDR | hsa-miR-15b-5p | Familiar ovarian carcinoma | MNDR-E-MI-18364 |
MNDR | hsa-miR-15b-5p | B-cell lymphoma | MNDR-E-MI-18365 |
MNDR | hsa-miR-15b-5p | Rheumatoid arthritis | MNDR-E-MI-18366 |
MNDR | hsa-miR-15b-5p | Retinoblastoma | MNDR-E-MI-18367 |
MNDR | hsa-miR-15b-5p | Barrett's adenocarcinoma | MNDR-E-MI-18368 |
MNDR | hsa-miR-15b-5p | Hodgkin disease | MNDR-E-MI-18369 |
MNDR | hsa-miR-15b-5p | Burkitt lymphoma | MNDR-E-MI-18370 |
MNDR | hsa-miR-15b-5p | Mouth neoplasms | MNDR-E-MI-18371 |
MNDR | hsa-miR-15b-5p | Psoriasis | MNDR-E-MI-18372 |
MNDR | hsa-miR-15b-5p | Acute myelogenous leukemia | MNDR-E-MI-18373 |
MNDR | hsa-miR-15b-5p | Colorectal cancer | MNDR-E-MI-18374 |
MNDR | hsa-miR-15b-5p | Nasopharynx carcinoma | MNDR-E-MI-18375 |
MNDR | hsa-miR-15b-5p | Type 2 diabetes mellitus | MNDR-E-MI-18376 |
MNDR | hsa-miR-15b-5p | Multiple myeloma | MNDR-E-MI-18377 |
MNDR | hsa-miR-15b-5p | Uterine cervical neoplasms | MNDR-E-MI-18378 |
MNDR | hsa-miR-15b-5p | Ependymoma | MNDR-E-MI-18379 |
MNDR | hsa-miR-15b-5p | Cardiac hypertrophy | MNDR-E-MI-18380 |
MNDR | hsa-miR-15b-5p | Nasopharyngeal cancer | MNDR-E-MI-18381 |
MNDR | hsa-miR-15b-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-18382 |
MNDR | hsa-miR-15b-5p | Stroke lacunar | MNDR-E-MI-18383 |
MNDR | hsa-miR-15b-5p | Barrett's carcinogenesis | MNDR-E-MI-18384 |
MNDR | hsa-miR-15b-5p | Breast cancer her3+ negative | MNDR-E-MI-18385 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | AGO2 | Homo sapiens | RR00055677 |
TOP